Le Qin

Key Laboratory Of Regenerative Biology South China Institute For Stem Cell Biology And Regenerative Medicine
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity.

DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity.

Journal: Science immunology

Published: March 21, 2025

Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.

Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.

Journal: Journal of translational medicine

Published: March 09, 2025

Correction: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.

Correction: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.

Journal: Journal of hematology & oncology

Published: February 25, 2025

Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.

Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.

Journal: Frontiers in immunology

Published: September 17, 2024

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.

Journal: Molecular therapy. Oncology

Published: September 15, 2023

CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects.

CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects.

Journal: Cell reports. Medicine

Published: July 12, 2023

The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.

The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.

Journal: International immunopharmacology

Published: March 07, 2023

BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells.

BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells.

Journal: The EMBO journal

Published: January 05, 2023

c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.

c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.

Journal: Cytotherapy

Published: November 25, 2022

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.

Journal: Cell reports

Published: October 03, 2022

A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone.

A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone.

Journal: Blood science (Baltimore, Md.)

Published: September 07, 2022

CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.

CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.

Journal: Clinical and experimental medicine

Published: September 05, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026